TY  - CHAP
M1  - Book, Section
TI  - Chapter 4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA
A1  - Paulmichl, Markus
A1  - Maliepaard, Marc
A1  - Papaluca, Marisa
A1  - Grimstein, Christian
A2  - Bertino, Joseph S.
A2  - DeVane, C. Lindsay
A2  - Fuhr, Uwe
A2  - Kashuba, Angela D.
A2  - Ma, Joseph D.
PY  - 2013
T2  - Pharmacogenomics: An Introduction and Clinical Perspective
AB  - Review  and  discuss  the  regulatory  considerations  for  pharmacogenomics  set  forth  by  the  European  Medicines  Agency  (EMA).Review  and  discuss  the  regulatory  considerations  for  pharmacogenomics  set  forth  by  the  US  Food  and  Drug  Administration  (FDA).Understand  how  these  regulatory  agencies  have  similarities  and  differences  in  their  rules  and  application.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/23
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=56875471
ER  -